Kangaroo Mother Care With Plastic Bag (Trials 1A & 1B)

November 4, 2022 updated by: Colm Travers, University of Alabama at Birmingham

Randomized Trials of Kangaroo Mother Care With Plastic Bag to Prevent Neonatal Hypothermia in Preterm Infants (Trial 1A and 1B)

The purpose of this study is to determine whether the combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care reduces the incidence of moderate (32-36° C) or severe (<32.0° C) hypothermia in preterm infants ≥ 32 to 36 6/7 weeks of gestational age (GA) when compared to KMC as continuously as possible together with routine WHO thermoregulation care.

Study Overview

Detailed Description

The purpose of this study is to determine whether the combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling) reduces the incidence of moderate hypothermia (32-36° C) or severe (<32.0° C) in preterm infants ≥ 32 to 36 6/7 weeks of gestational age (GA) when compared to KMC as continuously as possible together with routine WHO thermoregulation care, as practiced.

The investigators are proposing two trials, one protocol for infants 32-36 6/7 weeks (this one) and one for infants who are ≥37 weeks gestational age. This preterm infant trial will address the effectiveness of KMC in combination with plastic bags in decreasing hypothermia in preterm infants. The proposed trial will determine whether KMC with plastic bags prevents hypothermia in neonates born in a healthcare setting with limited resources where a high risk for hypothermia has been reported. Any intervention that decreases morbidity during the neonatal period has the potential to impact health beyond the neonatal period,and one that is highly cost-effective and easy to use is more likely to be implemented in the developing world.

Study Type

Interventional

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lusaka, Zambia
        • University Teaching Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

10 minutes to 2 hours (CHILD)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Estimated gestational age ≥32 0/7 - 36 6/7 weeks
  • Delivery in the hospital

Exclusion Criteria:

  • Abdominal wall defect or myelomeningocele
  • Major congenital anomalies
  • Blistering skin disorder
  • Clinically unstable mothers secondary to cardiovascular and pulmonary conditions
  • Infants requiring respiratory support beyond 10 minutes after birth
  • Infant requiring NICU admission
  • C/section
  • Multiple gestation if the last delivering infant is not born within 10 minutes from the time of birth of the first infant

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: PREVENTION
  • Allocation: RANDOMIZED
  • Interventional Model: PARALLEL
  • Masking: NONE

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
ACTIVE_COMPARATOR: KMC & WHO protocol (0-1 hour)
The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
ACTIVE_COMPARATOR: KMC & WHO protocol (1-24 hours)
The combination of Kangaroo Mother Care (KMC) as continuously as possible together with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
EXPERIMENTAL: KMC, WHO protocol & bag (0-1 hour)
The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
EXPERIMENTAL: KMC, WHO protocol & bag (1-24 hours
The combination of Kangaroo Mother Care (KMC) as continuously as possible together with the use of a plastic bag in combination with routine World Health Organization (WHO) thermoregulation care (warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Moderate or severe hypothermia at 1 hour after birth (Phase 1A)
Time Frame: 1 hour after birth
Moderate (32.0-35.9C) or severe (<32.0C) hypothermia at 1 hour after birth (via axillary temperature)
1 hour after birth
Moderate or severe hypothermia at 24 hours or discharge (Phase 1B)
Time Frame: 1 to 24 hours after birth
Moderate (32.0-35.9C) or severe (<32.0C) hypothermia at 24 hours or discharge whichever occurs first (via axillary temperature)
1 to 24 hours after birth

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Duration of KMC and plastic bag to infant's body temperature
Time Frame: During first 1 hour
Correlation analysis between duration of KMC +/- plastic bag in minutes to infant's body temperature in Celsius
During first 1 hour
Any hypothermia at 1 hour after birth (Phase 1A)
Time Frame: 1 hour after birth
Any hypothermia (<36.5C) at 1 hour after birth
1 hour after birth
Any hypothermia at 24 hours or discharge (Phase 1B)
Time Frame: 1 to 24 hours or discharge
Any hypothermia (<36.5C) at 24 hours or discharge, whichever occurs first
1 to 24 hours or discharge
Hyperthermia at 1 hour after birth (Phase 1A)
Time Frame: 1 hour after birth
Hyperthermia (>38.0C) at 1 hour after birth
1 hour after birth
Hyperthermia at 24 hours or discharge (Phase 1B)
Time Frame: 1 to 24 hours or discharge
Hyperthermia (>38.0C) at 24 hours or discharge, whichever occurs first
1 to 24 hours or discharge
Skin rash
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Skin rash (at 1hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Neonatal Intensive Care Unit admission
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Neonatal Intensive Care Unit admission (at 1 hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Respiratory distress syndrome
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Diagnosis of respiratory distress syndrome (at 1 hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Sepsis
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Diagnosis of sepsis (at 1hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Hypotension, hypoglycemia or seizure
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Diagnosis of any of the following; hypotension, hypoglycemia or seizure (at 1hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Death
Time Frame: 1hour to 24 hours or discharge, or whichever occurs first
Death (at 1hour and before discharge)
1hour to 24 hours or discharge, or whichever occurs first
Maternal body temperature
Time Frame: At birth, at 1 hour, every four hours until 24 hours or discharge, whichever occurs first
Maternal body temperature in Celsius
At birth, at 1 hour, every four hours until 24 hours or discharge, whichever occurs first
Duration of KMC and plastic bag to infant's body temperature
Time Frame: During first 24 hours or discharge, or whichever occurs first
Correlation analysis between duration of KMC +/- plastic bag in minutes to infant's body temperature in Celsius
During first 24 hours or discharge, or whichever occurs first

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (ANTICIPATED)

November 19, 2024

Primary Completion (ANTICIPATED)

October 12, 2025

Study Completion (ANTICIPATED)

October 12, 2025

Study Registration Dates

First Submitted

May 3, 2017

First Submitted That Met QC Criteria

May 3, 2017

First Posted (ACTUAL)

May 5, 2017

Study Record Updates

Last Update Posted (ACTUAL)

November 7, 2022

Last Update Submitted That Met QC Criteria

November 4, 2022

Last Verified

November 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Preterm Birth

Clinical Trials on KMC & WHO protocol (0-1 hour)

3
Subscribe